Quarterly ResultMay 11, 2026, 05:07 PM
Ernexa Therapeutics Q1 Net Loss $5.5M; Raises $9.5M in Public Offering
AI Summary
Ernexa Therapeutics Inc. reported a net loss of $5.5 million for Q1 2026, a decrease from $8.2 million in Q1 2025, which included a $2.0 million goodwill impairment charge. The company significantly improved its cash position by raising approximately $9.5 million in net proceeds from a public offering in February 2026. As of March 31, 2026, cash stood at $9.2 million, and the company also established an At-the-Market (ATM) program for up to $9.2 million to support future capital needs.
Key Highlights
- Net loss for Q1 2026 was $5.5 million, down from $8.2 million in Q1 2025.
- Accumulated deficit reached $251.1 million as of March 31, 2026.
- Cash balance increased to $9.2 million at March 31, 2026, from $1.9 million at Dec 31, 2025.
- Received $9.5 million in net proceeds from a public offering in February 2026.
- Recognized a $2.0 million non-cash goodwill impairment charge in Q1 2026.
- Established an ATM program to sell up to $9.2 million of common stock.
- Research and development expenses increased to $1.9 million from $1.3 million YoY.
- General and administrative expenses rose to $1.6 million from $1.4 million YoY.